COSMO Pharmaceuticals N.V. Logo

COSMO Pharmaceuticals N.V.

Specialty pharma for gastroenterology/dermatology, offering colon treatments & manufacturing services.

COPN | SW

Overview

Corporate Details

ISIN(s):
NL0011832936
LEI:
724500OX0EBQRYTVV639
Country:
Netherlands
Address:
Sir Rogerson's Quay Riverside II, Dublin 2 Dublin
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

COSMO Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing and commercializing products for gastroenterology, dermatology, and healthtech. The company's therapeutic focus is on the oral and endoscopic treatment of colon diseases, including bowel diseases and colorectal cancer prevention, utilizing its proprietary MMX® technology. In addition to its own pipeline, Cosmo provides manufacturing services to other pharmaceutical companies. These services cover the production of solid, semi-solid, and liquid oral medicines and include process assessment, technology transfer, stability testing, market release, and regulatory documentation support.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-07 02:00
Regulatory News Service
Cosmo Pharmaceuticals announces regulatory approval of Winlevi® in South Korea
English 5.2 KB
2025-10-07 02:00
Regulatory News Service
Cosmo Pharmaceuticals gibt die behördliche Zulassung von Winlevi® in Südkorea b…
German 6.2 KB
2025-08-27 02:00
Regulatory News Service
Cosmo Receives Positive CHMP Opinion for Winlevi® for Treatment of Acne in Adul…
English 7.4 KB
2025-08-27 02:00
Regulatory News Service
Cosmo erhält positive CHMP-Stellungnahme für Winlevi® zur Behandlung von Akne b…
German 8.8 KB
2025-08-08 02:00
Regulatory News Service
Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of O…
English 4.7 KB
2025-08-08 02:00
M&A Activity
Cosmo und Takeda verlängern ihre strategische Produktionsvereinbarung für die w…
German 5.0 KB
2025-08-06 02:00
Business and Financial Review
Cosmo Pharmaceuticals Confirms No Exposure to Proposed U.S. Tariffs and Reaffir…
English 3.3 KB
2025-08-06 02:00
Earnings Release
Cosmo Pharmaceuticals bestätigt, dass keine Auswirkungen durch geplante US-Zöll…
German 4.0 KB
2025-07-23 02:00
Earnings Release
Cosmo Delivers Strong Performance in H1 2025, Raises Full-Year EBITDA Guidance …
English 22.3 KB
2025-07-23 02:00
Earnings Release
Cosmo liefert starke Ergebnisse im ersten Halbjahr 2025, erhöht EBITDA-Guidance…
German 24.4 KB
2025-07-17 02:00
Regulatory News Service
Cosmo announces launch of Winlevi® for Treatment of Acne in Singapore and Malay…
English 9.5 KB
2025-07-17 02:00
Regulatory News Service
Cosmo: Markteinführung von Winlevi® zur Behandlung von Akne in Singapur und Mal…
German 10.7 KB
2025-07-16 02:00
Environmental & Social Information
Cosmo Accelerates Global ESG Leadership with Major Ratings Upgrades, UN Compact…
English 6.4 KB
2025-07-16 02:00
Environmental & Social Information
Cosmo baut Vorreiterrolle im Bereich ESG durch bedeutende Rating-Upgrades, die …
German 7.4 KB
2025-07-01 02:00
Investor Presentation
Cosmo Unveils Bold 2030 Vision and Strategy; launches AI-driven Growth Phase at…
English 8.4 KB

Automate Your Workflow. Get a real-time feed of all COSMO Pharmaceuticals N.V. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for COSMO Pharmaceuticals N.V. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden ELIC
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden ELN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel ENLV
Enorama Pharma AB Logo
Develops & makes consumer nicotine products & medicated gums, offering private label solutions.
Sweden ERMA
Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.
South Korea 183490
Enzymatica AB Logo
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden ENZY
Developing alopecia therapies, skin regeneration products, and preclinical CRO services.
South Korea 446440
EQL Pharma AB Logo
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden EQL
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France ERYP
EuBiologics Co., Ltd. Logo
Develops vaccines for global public health and provides biopharmaceutical CRMO services.
South Korea 206650

Talk to a Data Expert

Have a question? We'll get back to you promptly.